PATH-HHT, a Double-Blind, Randomized, Placebo-Controlled Trial in Hereditary Hemorrhagic Telangiectasia Demonstrates That Pomalidomide Reduces Epistaxis and Improves Quality of Life
Titel:
PATH-HHT, a Double-Blind, Randomized, Placebo-Controlled Trial in Hereditary Hemorrhagic Telangiectasia Demonstrates That Pomalidomide Reduces Epistaxis and Improves Quality of Life
Auteur:
Al-Samkari, Hanny Kasthuri, Raj S. Iyer, Vivek Pishko, Allyson M Decker, Jake E Whitehead, Kevin J Conrad, Miles B Weiss, Clifford Parambil, Joseph Zumberg, Marc Stuart Zhou, Jenny Y Boyer, Holly C Sutton, Vernon R Mazepa, Marshall Bradley, Lauren Clancy, Marianne S. Wisniewski, Lisa Carper, Benjamin Catellier, Diane Thomas, Sonia M McCrae, Keith R.